Spectral AI Research Partner Using DeepView System Wins Best Research Project at the 2025 Education Awards
Rhea-AI Summary
Positive
- None.
Negative
- None.
DALLAS, May 20, 2025 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (NASDAQ: MDAI) (“Spectral AI” or the “Company”), a leading developer of the AI-driven DeepView® System, which uses multi-spectral imaging and AI algorithms to predict burn healing potential today announced that its research partners, RCSI Skin Wounds and Trauma (SWaT) Research Center and RCSI Connolly Hospital, have been awarded Best Research Project at the 2025 Education Awards utilizing the DeepView System for their Diabetic Foot Ulcers (DFUs) project.
The Education Awards recognize, encourage and celebrate excellence in third-level education across Ireland, including both state-funded and private institutions. The awards are part of the BusinessRiver network, which connects more than 12,000 senior professionals through more than 30 award programs spanning a range of industries.
“This project highlights the innovative integration of real-time multispectral imaging with AI-driven analytics to guide faster and more effective evaluation and potential treatment strategies for diabetic foot ulcers. In working with our DeepView System, this award celebrates a remarkable cross-disciplinary research effort that brings together clinical, academic, and industry expertise,” said Michael DiMaio, Chairman of the Board. “This project was awarded the Best Research Project as it features an innovative use of AI and imaging for real-time wound assessment, showcasing the cutting-edge technology of the DeepView System in the pursuit of improved patient outcomes.”
“This award-winning research by our partners at RCSI is a significant milestone in validating the clinical value of our DeepView® System,” said Jeremiah Sparks, Chief Commercialization Officer of Spectral AI. “The real-world data generated in Ireland is not only expanding the clinical evidence base for DeepView but also helping shape our strategy for commercialization. These findings position us strongly as we prepare to bring DeepView to broader markets.”
About Spectral AI
Spectral AI, Inc. is a Dallas-based predictive AI company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, with initial applications involving patients with burns. The Company is working to revolutionize the management of wound care by “Seeing the Unknown®” with its DeepView® System. The DeepView® System is being developed as a predictive device to offer clinicians an objective and immediate assessment of a burn wound’s healing potential prior to treatment or other medical intervention. With algorithm-driven results and a goal of exceeding the current standard of care in the future, the DeepView® System is expected to provide fast and accurate treatment insight towards value care by improving patient outcomes and reducing healthcare costs. For more information about the DeepView® System, visit www.spectral-ai.com.
Forward-Looking Statements
Certain statements made in this release are “forward looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995, including statements regarding the Company’s strategy, plans, objectives, initiatives and financial outlook. When used in this press release, the words “estimates,” “projected,” “expects,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside Company’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. As such, readers are cautioned not to place undue reliance on any forward-looking statements.
Investors should carefully consider the foregoing factors, and the other risks and uncertainties described in the “Risk Factors” sections of the Company’s filings with the SEC, including the Registration Statement and the other documents filed by the Company. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements.
For Media and Investor Relations, please contact:
David Kugelman
Atlanta Capital Partners LLC
(866) 692-6847 Toll Free - U.S. & Canada
(404) 281-8556 Mobile and WhatsApp
Email: dk@atlcp.com
FAQ
What award did Spectral AI's research partners win at the 2025 Education Awards?
How does Spectral AI's DeepView System work for diabetic foot ulcers?
What is the significance of this award for MDAI stock?
Who are Spectral AI's research partners in this award-winning project?
